Direkt zum Inhalt | Direkt zur Navigation

Benutzerspezifische Werkzeuge

Sie sind hier: Startseite / Forschung / Studienregister


  • Allergologische Studien (Beschreibung)
  • Dermato-Onkologische Studien (malignes Melanom) (Beschreibung)
    • CA 224-047 Relatlimab (BMS):
    • IMCgp100-201: A Phase II/b Open-Label, Multi-Center Study of the Safety and Efficacy of IMCgp100 in Combination with Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab Compared with IMCgp100 Alone in Patients with Advanced Melanoma.
    • IMCgp 100-202:
    • ImmunoCobiVem: A Phase II, multicenter, open-Label, randomized-controlled Trial evaluating the efficacy and safety of a sequencing schedule of cobimetinib plus vemurafenib followed by immunotherapy wíth an anti-PD-L1 antibody atezolizumab for the Treatment in patients with unresectable or metastatic BRAF V600 Mutant melanoma.
    • Logic-2:
    • Trilogy (CO39262): A phase III, double-blinded, randomized, Placebo-controlled study of Atezolizumab plus Cobimetinib and Vemurafenib versus Placebo plus Cobimetinib and Vemurafenib in previously untreated BRAF V600 mutation-positive patients with metastatic or unresectable locally advanced Melanoma.
  • Dermato-Onkologische Studien (Merkelzellkarzinom) (Beschreibung)
    • EMR 100070-003, Part B: A Phase II, open-Label, multicenter Trial to investigate the clinical activity and safety of avelumab (MSB0010718C) in subjects with Merkel cell carcinoma.
  • Dermato-Onkologische Studien (kutane Lymphome) (Beschreibung)
    • 4SC-RESMAIN Studie: A multicentre, double blind, randomised, Placebo-controllend, Phase II Trial to evaluate Resminostat for maintenance Treatment of patients with advanced stage (stage IIB-IVB) mycosis fungoides (MFI or Sezary Syncdrome (SS) that have achieved disease control with systemic therapy - the RESMAIN Study
  • Dermato-Onkologische Studien (Basalzellkarzinom) (Beschreibung)
  • Kollagenosen/Sklerodermie (Beschreibung)
    • DNSS e. V. - Deutsches Netzwerk für Sklerodermie: The German Network for Systemic Scleroderma (DNSS)
    • PREDICT: A two-stage multicenter study to investigate and evaluate the predictive value of laboratory and clinical parameters for digital ulcers in patients with systemic sclerosis
  • Wundheilungsstörungen
  • Psoriasis
  • Mastozytose (Beschreibung)
  • Andere